Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.

Journal Article (Journal Article;Review)

Glioblastoma is the most common primary malignant brain tumor in adults and outcomes remain poor despite the current standard of care multimodal therapy. Oncolytic virotherapy utilizes engineered viruses to exert an anti-tumor effect via both direct oncolysis and stimulation of an immune response within the tumor microenvironment, turning tumors from "cold" to "hot." This has shown promise as a novel therapeutic modality and attempts to circumvent the challenges associated with traditional treatments. Many oncolytic viruses have been investigated in completed and ongoing clinical trials and while safety has been demonstrated, clinical outcomes have been variable, often with only a subgroup of patients showing a significant response. This review summarizes these studies, addresses relevant technical aspects of oncolytic virus administration, and highlights practical considerations to assist providers in appropriately caring for patients treated with oncolytic virotherapy. Additionally, future directions within the field that may help to maximize efficacy of this modality are discussed.

Full Text

Duke Authors

Cited Authors

  • Shoaf, ML; Desjardins, A

Published Date

  • October 2022

Published In

Volume / Issue

  • 19 / 6

Start / End Page

  • 1818 - 1831

PubMed ID

  • 35674873

Pubmed Central ID

  • PMC9723031

Electronic International Standard Serial Number (EISSN)

  • 1878-7479

Digital Object Identifier (DOI)

  • 10.1007/s13311-022-01256-1


  • eng

Conference Location

  • United States